Trials / Unknown
UnknownNCT04913571
Tislelizumab in Combination With Eribulin for Patients With Metastatic Previously heaviLy-treAted TriplE-negative Breast Cancer：A Prospective Multiple-center Phase II Study
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 265 (estimated)
- Sponsor
- Fudan University · Academic / Other
- Sex
- Female
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
Triple-negative breast cancer (TNBC) lacks effective treatment options due to the absence of traditional therapeutic targets.This study is a multicentre, prospective trial. The primary objective of the trial was to evaluate the objective response rate to tslelizumab combined with eribulin in different subgroups（subgroup A: TMB High, B: PD-L1 positive，C, immunomodulatory (IM)，D，NanoString superiority，E，other types）of relapse or metastasis TNBC after failure of second-line chemotherapy. Therefore, exploring new therapeutic options and identifying subgroups of patients who may benefit from special treatments has been a focal point of research. Doing so, we expect to guide new investigation efforts in this area.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Eribulin | Eribulin |
| DRUG | Tislelizumab | Tislelizumab |
Timeline
- Start date
- 2021-05-27
- Primary completion
- 2022-06-01
- Completion
- 2023-06-01
- First posted
- 2021-06-04
- Last updated
- 2021-06-04
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04913571. Inclusion in this directory is not an endorsement.